Navigation Links
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
Date:1/9/2009

LONDON, RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Jan. 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

The FDA had requested that the data in a single study be reformatted. In addition, GSK conducted a review of other clinical studies taking this input into account. The withdrawal was not related to the content of the filing.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Solzira - is a new chemical entity that is designed to improve upon the pharmacokinetics of gabapentin by taking advantage of high-capacity transport mechanisms in the gastrointestinal tract to improve absorption.

XenoPort - is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilise the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in partnership with Astellas Pharma Inc. and GSK. As announced today, GSK has resubmitted to the FDA an NDA for Solzira for the treatment of moderate-to-severe primary RLS. XenoPort's product candidates are also being studied for the potential treatment of gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity related to spinal cord injury, acute back spasms and Parkinson's disease. To lea
'/>"/>

SOURCE GlaxoSmithKline; XenoPort, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
2. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
3. OmegaGenesis Announces Angiogenesis Application Collaboration
4. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. Call for Applications: The Amgen Award for Science Teaching Excellence
7. Savient Submits Biologics License Application (BLA) for pegloticase
8. GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
9. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
10. Penn State gets $5M NSF grant for Nanotech Applications and Career Knowledge
11. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the ... industry, recently announced the formation of the company,s Medical ... announce the addition of Dr. William E. Gannon, ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with ... variety of therapeutic areas and set strategic goals for ...
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3
... N.C., July 23 Best Practices, LLC is ... world-leader in the,field of best practice benchmarking focused ... industries. Best Practices, LLC is,conducting business function specific ... Web-Conferences Scheduled in July 2008, Best ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) announced the ... Doshi and the appointment as a Director of the,Company ... -,Business Strategies of the Company, effective July 22, 2008., ... of Business,Strategies in July 2007, Mr. Singh served as ...
... July 23 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" ... or similar regulatory authorities in the Provinces,of British ... the,cease trade orders against the Company effective July ... cease trade orders outstanding against the,Company., The ...
Cached Biology Technology:Web-Conferences by Best Practices, LLC for July 2008 2Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva 2Chromos Announces Full Revocation of Cease Trade Orders 2
(Date:8/19/2014)... To improve students, chances of completing introductory ... of Houston (UH) implemented a comprehensive student success ... for failure. , Through a grant from ... Department of Biology and Biochemistry embarked on a ... Biology" for non-majors and "Introductory Biology" for science ...
(Date:8/19/2014)... not a monkey. It,s not a lemur. It,s not an ... Philippine tarsier: a tiny, adorable and downright "cool" primate from ... Americans are familiar with," said Rafe Brown, curator-in-charge at the ... and ears; an extremely cute, furry body; a long tail ... fingers and toe tips that look a bit like the ...
(Date:8/19/2014)... Two Northwestern University scientists have identified a biomarker ... aggressive carcinoma that is resistant to many types ... provides a smart target for new therapeutics designed ... breast cancer patient data taken from The Cancer ... Robert W. Tell used powerful computational and bioinformatics ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... Using morphine to fight the pain associated with abdominal ... even tripling the amount of time it takes to ... the University of Colorado Boulder. The research team ... Grace, a postdoctoral research fellow, together with Erika Galer, ...
... from as many photons as possible is imperative. ... engineering researchers on a quest to boost the energy-absorption ... running up against limits set by the laws of ... of Pennsylvania and Drexel University have experimentally demonstrated a ...
... BURLINGTON, Mass. , Nov. 12, 2013  Decision Resources, ... for pharmaceutical and healthcare issues, finds that while most ... play a critical role in pharmaceutical development of chronic ... outside of oncology is building. The Strategic Insights report ...
Cached Biology News:Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find 2Penn and Drexel team demonstrates new paradigm for solar cell construction 2Penn and Drexel team demonstrates new paradigm for solar cell construction 3Penn and Drexel team demonstrates new paradigm for solar cell construction 4Penn and Drexel team demonstrates new paradigm for solar cell construction 5Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing 2
... kit for determining the absolute count of ... mobilized peripheral blood samples, and leukapheresis samples. ... nucleated cell count and a total CD45 ... for use in the BD Procount progenitor ...
... to Protein A and, until recently, no readily ... IgM purification. Standard methods for IgM purification generally ... effective for removing all of the major impurities ... Pierce has developed an easy-to-use affinity matrix ...
... compact and lightweight, the Moticam 2300 camera ... the eyepiece, eyetube, or trinocular port. Included ... use Plug-and-Play Images 2.0ML software offers quick ... tools to maximize resolution for examination or ...
... Merck KGaA. Physical form: Solution in 50% glycerol containing ... 2 , and 20 mM NaCl Preparation Unit Definition: ... acid-soluble oligonucleotides equivalent to a ΔA 260 of ... C (reaction volume 2.625 ml). Assay: SDS-PAGE ≥ ...
Biology Products: